Suchergebnisse - "Anurag, Meenakshi"

PubPharm (7)

1

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination : A Phase 3 Randomized Clinical Trial

enthalten in: JAMA oncology | 2024

von Ma, C. | Suman, V. | Sanati, S. | +27

2

Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment

enthalten in: Cancer research communications | 2023

von Kim, B. | Zheng, Z. | Lei, J. | +22

3

Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Suman, V. | Du, L. | Hoskin, T. | +6

4

Endocrine therapy resistance : new insights

enthalten in: Breast (Edinburgh, Scotland) | 2019

von Lei, J. | Anurag, M. | Haricharan, S. | +2

5

Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2018

von Anurag, M. | Punturi, N. | Hoog, J. | +3

6

The prognostic effects of somatic mutations in ER-positive breast cancer

enthalten in: Nature communications | 2018

von Griffith, O. | Spies, N. | Anurag, M. | +30

ErratumIn: Nat Commun. 2018 Nov 14;9(1):4850. - PMID 30429476

7

Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer

enthalten in: Cancer discovery | 2017

von Haricharan, S. | Punturi, N. | Singh, P. | +16

1
[1]